BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Persson E, Bolt G, Steenstrup TD, Ezban M. Recombinant coagulation factor VIIa – from molecular to clinical aspects of a versatile haemostatic agent. Thrombosis Research 2010;125:483-9. [DOI: 10.1016/j.thromres.2009.11.027] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Lauritzen B, Hilden I. Concizumab promotes haemostasis via a tissue factor-factor VIIa-dependent mechanism supporting prophylactic treatment of haemophilia: Results from a rabbit haemophilia bleeding model. Haemophilia 2019;25:e379-82. [PMID: 31609513 DOI: 10.1111/hae.13861] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Lu J, Liao L, Geng Y, Wang X, Tong Z, Ke L, Li W, Li N, Li J. A double-blind, randomized, controlled study to explore the efficacy of rFVIIa on intraoperative blood loss and mortality in patients with severe acute pancreatitis. Thrombosis Research 2014;133:574-8. [DOI: 10.1016/j.thromres.2014.01.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Bar-ilan A, Livnat T, Hoffmann M, Binder L, Zakar M, Guy R, Felikman Y, Moschcovich L, Shenkman B, Monroe D, Hershkovitz O, Kenet G, Hart G. In vitro characterization of MOD-5014, a novel long-acting carboxy-terminal peptide (CTP)-modified activated FVII. Haemophilia 2018;24:477-86. [DOI: 10.1111/hae.13428] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
4 Mitrophanov AY, Reifman J. Kinetic modeling sheds light on the mode of action of recombinant factor VIIa on thrombin generation. Thrombosis Research 2011;128:381-90. [DOI: 10.1016/j.thromres.2011.05.013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
5 Craik CS, Page MJ, Madison EL. Proteases as therapeutics. Biochem J 2011;435:1-16. [PMID: 21406063 DOI: 10.1042/BJ20100965] [Cited by in Crossref: 122] [Cited by in F6Publishing: 41] [Article Influence: 11.1] [Reference Citation Analysis]
6 Puetz J. Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients. Drug Des Devel Ther 2010;4:127-37. [PMID: 20689699 DOI: 10.2147/dddt.s6628] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
7 Kandane-rathnayake RK, Isbister JP, Zatta AJ, Aoki NJ, Cameron P, Phillips LE; on behalf of the Australian and New Zealand Haemostasis Registry Steering Committee. Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding: Experience from the Haemostasis Registry. ANZ J Surg 2013;83:155-60. [DOI: 10.1111/j.1445-2197.2012.06285.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
8 Plesner B, Westh P, Nielsen AD. The effect of GlycoPEGylation on the physical stability of human rFVIIa with increasing calcium chloride concentration. European Journal of Pharmaceutics and Biopharmaceutics 2011;78:222-8. [DOI: 10.1016/j.ejpb.2010.12.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
9 Demartis F, Batorova A, Chambost H, Eshghi P, Karimi M, Kavakli K, El Fegoun SB, Cepo K, Vestergaard LS, Benson G. Real-World Early Treatment with Room Temperature-Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses. TH Open 2017;1:e130-8. [PMID: 31249918 DOI: 10.1055/s-0037-1608943] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Rand KD. Pinpointing changes in higher-order protein structure by hydrogen/deuterium exchange coupled to electron transfer dissociation mass spectrometry. International Journal of Mass Spectrometry 2013;338:2-10. [DOI: 10.1016/j.ijms.2012.08.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
11 Salas J, Liu T, Lu Q, Kulman JD, Ashworth T, Kistanova E, Moore N, Pierce GF, Jiang H, Peters R. Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion. Thrombosis Research 2015;135:970-6. [DOI: 10.1016/j.thromres.2014.12.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
12 Levy GG, Asikanius E, Kuebler P, Benchikh El Fegoun S, Esbjerg S, Seremetis S. Safety analysis of rFVII a with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program. J Thromb Haemost 2019;17:1470-7. [DOI: 10.1111/jth.14491] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
13 Branchini A, Baroni M, Pfeiffer C, Batorova A, Giansily-blaizot M, Schved J, Mariani G, Bernardi F, Pinotti M. Coagulation factor VII variants resistant to inhibitory antibodies. Thromb Haemost 2017;112:972-80. [DOI: 10.1160/th14-03-0198] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
14 Chitlur M. Challenges in the laboratory analyses of bleeding disorders. Thrombosis Research 2012;130:1-6. [DOI: 10.1016/j.thromres.2012.03.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
15 Ninan N, Muthiah M, Park I, Wong TW, Thomas S, Grohens Y. Natural Polymer/Inorganic Material Based Hybrid Scaffolds for Skin Wound Healing. Polymer Reviews 2015;55:453-90. [DOI: 10.1080/15583724.2015.1019135] [Cited by in Crossref: 38] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
16 Balestra D, Branchini A. Molecular Mechanisms and Determinants of Innovative Correction Approaches in Coagulation Factor Deficiencies. Int J Mol Sci 2019;20:E3036. [PMID: 31234407 DOI: 10.3390/ijms20123036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
17 Ivanciu L, Camire RM. Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity. Blood 2015;126:94-102. [PMID: 25896653 DOI: 10.1182/blood-2015-03-634329] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
18 Weber A, Minibeck E, Scheiflinger F, Turecek PL. Development of a lectin binding assay to differentiate between recombinant and endogenous proteins in pharmacokinetic studies of protein-biopharmaceuticals. J Pharm Biomed Anal 2015;108:21-8. [PMID: 25703236 DOI: 10.1016/j.jpba.2015.01.047] [Reference Citation Analysis]
19 Butros L, Boayue K, Mathew P. Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa. Drug Des Devel Ther 2011;5:275-82. [PMID: 21625417 DOI: 10.2147/DDDT.S17722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
20 Quade-Lyssy P, Abriss D, Milanov P, Ungerer C, Königs C, Seifried E, Schüttrumpf J. Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A. J Thromb Haemost 2014;12:1861-73. [PMID: 25224783 DOI: 10.1111/jth.12731] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
21 Kavakli K, Demartis F, Karimi M, Eshghi P, Neme D, Chambost H, Sommer L, Zak M, Benson G. Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study. Haemophilia 2017;23:575-82. [PMID: 28440004 DOI: 10.1111/hae.13227] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Chevreux G, Tilly N, Leblanc Y, Ramon C, Faid V, Martin M, Dhainaut F, Bihoreau N. Biochemical characterization of LR769, a new recombinant factor VIIa bypassing agent produced in the milk of transgenic rabbits. Haemophilia 2017;23:e324-34. [PMID: 28594467 DOI: 10.1111/hae.13253] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]